Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) EBT (2019 - 2025)

BridgeBio Pharma's EBT history spans 7 years, with the latest figure at -$194.8 million for Q4 2025.

  • For Q4 2025, EBT rose 19.81% year-over-year to -$194.8 million; the TTM value through Dec 2025 reached -$668.2 million, down 33.19%, while the annual FY2025 figure was -$732.5 million, 35.1% down from the prior year.
  • EBT for Q4 2025 was -$194.8 million at BridgeBio Pharma, down from -$150.7 million in the prior quarter.
  • Across five years, EBT topped out at -$19.1 million in Q1 2024 and bottomed at -$242.9 million in Q4 2024.
  • The 5-year median for EBT is -$161.3 million (2021), against an average of -$152.4 million.
  • The largest annual shift saw EBT skyrocketed 86.59% in 2024 before it plummeted 640.71% in 2025.
  • A 5-year view of EBT shows it stood at -$180.6 million in 2021, then rose by 19.62% to -$145.1 million in 2022, then plummeted by 32.37% to -$192.1 million in 2023, then fell by 26.42% to -$242.9 million in 2024, then rose by 19.81% to -$194.8 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's EBT are -$194.8 million (Q4 2025), -$150.7 million (Q3 2025), and -$181.7 million (Q2 2025).